Navigation Links
Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
Date:9/13/2007

AMSTERDAM, September 13 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that it has appointed Hessel J. H. M. Lindenbergh as Chairman of its Supervisory Board.

Hessel Lindenbergh is a former member of the managing board of ING Group N.V.. Currently, Mr. Lindenbergh is chairman of the supervisory board of NIB Capital N.V. and board member of the Royal Numico, Petroplus International and Gamma Holding. Mr. Lindenbergh is also a member of the board of directors of the University of Amsterdam (UvA) and Senior Counsel at the Boer & Croon.

Agendia's other supervisory board directors are Prof. Dr. Wim van Harten from the Netherland's Cancer Institute (NKI), Pieter van der Meer from Gilde Health Care, Gertjan van der Baan from van Herk Biotech B.V., and Dr. Gosse Bruisma, an independent member.

In making this announcement, Agendia's CEO, Dr. Bernhard Sixt, stated: "We are very pleased that Mr. Hessel Lindenbergh has accepted the chair of the company's Supervisory Board bringing along a tremendous international reputation in the financial business. We are convinced that our Supervisory Board will contribute to further build the company strategically and to accelerate the commercial success of Agendia."

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(i), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(i) CupPrint(R) is based on a license to the TUA database of AviaraDx

(ii) RNAretain(R) is a trademark of Asuragen Inc.


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... waist circumference, and increased serum leptin levels had a positive association with increased ... The study published in the International Neurourology Journal involved 571 Korean men ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... science through unique partnerships, seeks outstanding early career nominees for the 2017 New ... to meeting the needs of a world in which one in nine people ...
(Date:1/24/2017)... , Jan. 23, 2017   Instrument Business Outlook ... Minneapolis, MN ) the 2016 Company ... most authoritative newsletter tracking developments in the analytical ... "Bio-Techne consistently achieved outstanding technical, operational and ... Managing Editor of IBO. "In 2016, Bio-Techne capitalized ...
(Date:1/23/2017)... , Jan. 23, 2017   Enteris BioPharma, ... study agreement with Sanofi to leverage Enteris, ... platform, Peptelligenceā„¢, to develop an oral formulation of one ... Joel Tune , Chief Executive Officer and Executive Chairman ... further validation of the tremendous value our Peptelligence platform ...
Breaking Biology Technology:
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the ... Counting technology, entered into a license and supply agreement ... science. The agreement provides Singulex access to Thermo Scientific ... Europe is used to diagnose systemic bacterial ... States to aid in assessing the risk ...
Breaking Biology News(10 mins):